Mohammed T. Abou-Saleh

262 PRINCIPLES AND PRACTICE OF GERIATRIC PSYCHIATRY19. Cash R, Dennis T, L’Heureux Y et al. Parkinson’s disease anddementia: norepinephrine and dopamine in locus coeruleus.Neurology 1987; 37: 42–6.20. Ince PG, Perry EK, Morris CM. Dementia with Lewy bodies. Adistinct non-Alzheimer dementia syndrome? Brain Pathol 1998; 8:299–324.21. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewybody disease: progressive dementia with abundant cortical Lewybodies and senile changes of varying degree—a new disease? ClinNeuropathol 1984; 3: 185–92.22. Dickson DW, Davies P, Mayeux R et al. Diffuse Lewy body disease.Neuropathological and biochemical studies of six patients. ActaNeuropathol 1987; 75: 8–15.23. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with andwithout dementia: a clinicopathological study of 35 cases. ClinNeuropathol 1988; 7: 299–305.24. Gibb WRG, Esiri MM, Lees AJ. Clinical and pathological features ofdiffuse cortical Lewy body disease (Lewy body dementia). Brain 1987;110: 1131–53.25. Gibb WRG, Luthert PJ, Janota I, Lantos PL. Cortical Lewy bodydementia: clinical features and classification. J Neurol NeurosurgPsychiat 1989; 52: 185–92.26. Bradley R. Bovine spongiform encephalopathy: the need forknowledge, balance, patience and action. J Pathol 1990; 160:283–5.27. Roos R, Gajdusek DC, Gibbs CJ Jr. The clinical characteristics oftransmissible Creutzfeldt–Jakob disease. Brain 1973; 96: 1–20.28. Traub R, Gajdusek DC, Gibbs CJ Jr. Transmissible virusdementia: the relation of transmissible spongiformencephalopathy of Creutzfeldt–Jakob disease. In Smith WL,Kinsbourne M, eds, Aging and Dementia. New York: Spectrum,1977; 91–146.29. Brown P, Cathala F, Raubertas RF et al. The epidemiology ofCreutzfeldt–Jakob disease: conclusion of a 15 year investigationin France and review of the world literature. Neurology 1987; 37:895–904.30. Will RG, Matthews WB, Smith PG, Hudson C. A retrospectivestudy of Creutzfeldt–Jakob disease in England and Wales, 1970–1979. II: Epidemiology. J Neurol Neurosurg Psychiat 1986; 49:749–55.31. Harries-Jones R, Knight R, Will RG et al. Creutzfeldt–Jakob diseasein England and Wales, 1980–1984: a case-control study of potentialrisk factors. J Neurol Neurosurg Psychiat 1988; 57: 1113–19.32. Kahana E, Alter M, Braham J, Sofer D. Creutzfeldt–Jakob disease:focus among Libyan Jews in Israel. Science 1974; 183: 90–1.33. Masters CL, Harris JO, Gajdusek DC et al. Creutzfeldt–Jakobdisease: patterns of worldwide occurrence and the significance offamilial and sporadic clustering. Ann Neurol 1979; 5: 177–88.34. Masters CL, Gajdusek DC, Gibbs CJ Jr. Creutzfeldt–Jakob disease:virus isolation from the Gerstmann–Straussler syndrome. Brain 1981;104: 559–88.35. Baker HF, Ridley RM, Crow TJ. Experimental transmission of anautosomal dominant spongiform encephalopathy: does theinfective agent originate in the human genome? Br Med J 1985;291: 299–302.36. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt–Jakob disease in the UK. Lancet 1996; 347: 921–5.36a. Lorains JW, Henry C, Agbamu DA et al. Variant Creutzfeldt–Jakobdisease in an elderly patient. Lancet 2001; 357: 1339–40.37. Manuelidis EE. Creutzfeldt–Jakob disease. J Neuropathol Exp Neurol1985; 44: 1–17.38. Corsellis JAN. The transmissibility of dementia. Br Med Bull 1986;42: 111–14.39. Prusiner SB. Novel proteinaceous infectious particles cause scrapie.Science 1982; 216: 136–44.40. Prusiner SB, Gabizon R, McKinley MP. On the biology of prions.Acta Neuropathol 1987; 72: 299–314.41. Hsiao K, Prusiner SB. Inherited human prion diseases. Neurology1990; 40: 1820–7.42. Hsiao K, Meiner Z, Khana E et al. Mutation of the prion protein inLibyan Jews with Creutzfeldt–Jakob disease. N Engl J Med 1991; 324:1091–7.43. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition toiatrogenic Creutzfeldt–Jakob disease. Lancet 1991; 337: 1441–2.44. Brown P, Kaur P, Sulima MP et al. Real and imaginedclinicopathological limits of ‘‘prion dementia’’. Lancet 1993; 341:127–9.45. Martin JB. Huntington’s disease: new approaches to an old problem.Neurology 1984; 34: 1059–72.46. Gusella JF, Wexler NS, Conneally PM et al. A polymorphic DNAmarker genetically linked to Huntington’s disease. Nature 1983; 306:234–8.47. Vonsattel J-P, Myers RH, Stevens TJ et al. Neuropathologicalclassification of Huntington’s disease. J Neuropathol Exp Neurol1985; 44: 559–77.48. Myers RH, Vonsattel J-P, Stevens TJ et al. Clinical andneuropathologic assessment of severity in Huntington’s disease.Neurology 1988; 38: 341–7.49. Richardson EP. Huntington’s disease: some recent neuropathologicalstudies. Neuropathol Appl Neurobiol 1990; 16: 451–60.50. Roos RAC, Pruyt JFM, de Vries J, Bots GTAM. Neuronaldistribution in the putamen in Huntington’s disease. J NeurolNeurosurg Psychiatr 1985; 48: 422–5.51. Graveland GA, Williams RS, DiFiglia M. Evidence for degenerativeand regenerative changes in neostriatal spiny neurons in Huntington’sdisease. Science 1985; 227: 770–3.52. Graveland GA, Williams RS, DiFiglia M. A Golgi study of thehuman neostriatum: neurons and afferent fibres. J Comp Neurol 1985;234: 317–33.53. Ferrante RJ, Beal MF, Kowall NW et al. Sparing ofacetylcholinesterase-containing striatal neurons in Huntington’sdisease. Brain Res 1987; 411: 162–6.54. Ferrante RJ, Kowall NW, Beal MF et al. Morphologic andhistochemical characteristics of a spared subset of striatal neuronsin Huntington’s disease. J Neuropathol Exp Neurol 1987; 46: 12–27.55. Bird ED, Iversen LL. Huntington’s chorea: post-mortemmeasurements of glutamic acid decarboxylase, cholineacetyltransferase and dopamine in basal ganglia. Brain 1974; 97:457–72.56. Walling HW, Baldassare JJ, Westfall TC. Molecular aspects ofHuntington’s disease. J Neurosci Res 1998; 54: 301–8.57. Nasir J, Goldberg YP, Hayden MR. Huntington disease: new insightsinto the relationship between CAG expansion and disease. Hum MolGen 1996; 5: 1431–5.58. Wellington CL, Brinkman RR, O’Kusky JR, Hayden MR. Towardsunderstanding the molecular pathology of Huntington’s disease.Brain Pathol 1997; 7: 979–1002.59. Tabrizi SJ, Cleeter MW, Xuereb J et al. Biochemical abnormalitiesand excitotoxicity in Huntington’s disease brain. Ann Neurol 1999; 45:25–32.60. de la Monte SM, Vonsattel J-P, Richardson EP Jr. Morphometricdemonstration of atrophic changes in the cerebral cortex, whitematter and neostriatum in Huntington’s disease. J Neuropathol ExpNeurol 1988; 47: 516–25.61. Cudkowicz M, Kowall NW. Degeneration of pyramidalprojection neurons in Huntington’s disease cortex. Ann Neurol1990; 27: 200–4.62. Sotrel A, Myers RH. Morphometric analysis of prefrontal cortex inHuntington’s disease (HD). J Neuropathol Exp Neurol 1990; 49: 346.63. Braak H, Braak E. Allocrotical involvement in Huntington’s disease.Neuropathol Appl Neurobiol 1992; 18: 539–47.64. Ferrante RJ, Kowall NW, Richardson EP Jr. Neuronal and neuropilloss in the substantia nigra in Huntington’s disease. J NeuropatholExp Neurol 1989; 48: 380.65. Mann DMA. Subcortical afferent projection systems in Huntington’schorea. Acta Neuropathol 1989; 78: 551–4.66. Mann DM. Dementia of frontal type and dementias with subcorticalgliosis. Brain Pathol 1998; 8: 325–38.67. Bergeron C, Davis A, Pollanen MS. Pick’s disease is a unique anddistinct disease. Brain Pathol 2000; 10: 495–6.68. Jackson M, Lennox G, Lowe J. Motor neurone disease-inclusiondementia. Neurodegeneration 1996; 5: 339–50.69. Mann DMA, McDonagh AM, Snowden J et al. Molecularclassification of the dementias. Lancet 2000; 355: 626.70. Verny M, Jellinger KA, Hauw JJ et al. Progressive supranuclearpalsy: a clinicopathological study of 21 cases. Acta Neuropathol 1996;91: 427–31.